文献速递外周动脉疾病

Stellarex低剂量紫杉醇药物涂层球囊无死亡信号:ILLUMENATE Pivotal 4年结果

No Mortality Signal With Stellarex Low-Dose Paclitaxel DCB: ILLUMENATE Pivotal 4-Year Outcomes.
PubMed 文献 · J Endovasc Ther · 2022-01-08

ILLUMENATE Pivotal是一项在43个美国和欧盟中心开展的多中心、单盲随机对照试验,比较Stellarex低剂量紫杉醇药物涂层球囊与经皮腔内血管成形术治疗股腘动脉病变的远期安全性和有效性。结果显示DCB组36个月一期通畅率显著高于PTA组(p=0.016),48个月全因死亡率DCB组15.6%与PTA组15.2%无差异(p=0.929)。

要点

  • DCB组36个月一期通畅率显著高于PTA组(p=0.016)
  • 48个月主要不良事件率DCB组32.9% vs PTA组37.9%(p=0.428)
  • 48个月死亡率DCB组15.6% vs PTA组15.2%(p=0.929),无死亡信号

核心结论

  • Stellarex DCB与PTA相比3年内通畅率显著更高,4年内未检测到死亡率差异。
  • ILLUMENATE Pivotal随机对照试验数据支持低剂量Stellarex DCB的长期安全性和有效性。

研究设计与样本

  • ILLUMENATE Pivotal为多中心、单盲随机对照试验,在43个美国和欧盟中心开展。
  • 研究比较Stellarex DCB与PTA治疗股腘动脉病变的安全性和有效性。
  • 对所有在组患者在36和48个月时进行评估,并收集正式退出研究患者的生命状态。

主要发现

  • DCB组36个月一期通畅率显著高于PTA组(p=0.016)。
  • 36个月主要安全终点DCB组为77.4%,PTA组为72.4%(p=0.377)。
  • Kaplan-Meier分析显示DCB组在所有研究访视点无事件比例均高于PTA组。
  • 48个月主要不良事件率DCB组为32.9%,PTA组为37.9%(p=0.428)。
  • 48个月随访死亡率DCB组为15.6%,PTA组为15.2%(p=0.929),无差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Paclitaxel-coated balloons have shown safety and efficacy in the short- to intermediate-term; however, long-term data remain limited. OBJECTIVES: To report late safety and efficacy outcomes for a low-dose paclitaxel drug-coated balloon (DCB) compared with percutaneous transluminal angioplasty (PTA) in femoropopliteal lesions from a large randomized controlled trial (RCT). METHODS: ILLUMENATE Pivotal is a multicenter, single-blind RCT conducted across 43 US and EU centers to examine the safety and efficacy of the Stellarex DCB for the treatment of femoropopliteal disease. Assessments were recorded for all active patients at 36 and 48 months. Vital status of patients formally exited from the study was also collected. RESULTS: Primary patency through 36 months for patients treated with DCB was significantly higher compared with PTA (p=0.016). The primary safety endpoint through 36 months was 77.4% and 72.4%, respectively (p=0.377). Kaplan-Meier analysis indicated that a higher proportion of DCB subjects were event-free compared with PTA at all study visits. The rate of major adverse event (MAE) through 48 months was 32.9% in the DCB group and 37.9% in the PTA group (p=0.428). No differences in the rate of mortality were evident through 48 months of follow-up with 15.6% in the DCB group and 15.2% in the PTA group (p=0.929). CONCLUSIONS: Stellarex DCB was associated with significantly higher patency compared with PTA through 3 years with no mortality difference detected through 4 years. The data from the ILLUMENATE Pivotal RCT support the long-term safety and efficacy of the low-dose Stellarex DCB.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Lyden SP, Faries PL, Niazi KAK, et al. No Mortality Signal With Stellarex Low-Dose Paclitaxel DCB: ILLUMENATE Pivotal 4-Year Outcomes. J Endovasc Ther. 2022. PMID: 35000470. doi:10.1177/15266028211068769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。